Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zovirax Sales Force To Increase Six Fold Based On Biovail Agreement With Sciele

This article was originally published in The Pink Sheet Daily

Executive Summary

Promotional deal includes profit-sharing arrangement based on revenue targets for an initial term of five years.

You may also be interested in...



Biovail Axes U.S. Commercial Organization, Seeks Promotional Partner For Zovirax

With the potential entry of generic Wellbutrin XL looming, Biovail cuts 200-person commercial organization in the U.S.

First Horizon To Promote Fortamet, Altroprev With 100-Rep Sales Force

Andrx divests extended-release metformin and extended-release lovastatin to First Horizon for upfront payment of $50 mil. First Horizon's promotional efforts will focus on growing Fortamet and stabilizing Altoprev's declining market share.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel